Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND)

International Journal of Clinical Practice
K G ParhoferA Ptaszynska

Abstract

Intervention studies have shown that angiotensin receptor blockers (ARB) may reduce the incidence of type 2 diabetes mellitus. It is currently unclear whether short-term therapy with ARBs affects metabolic parameters. i-RESPOND, a randomised, controlled, multicentre, double-blind study evaluated the effect of 16 weeks of irbesartan vs. hydrochlorothiazide (HCTZ) on insulin resistance as well as on lipid and inflammatory parameters in hypertensive subjects with metabolic syndrome. Patients received irbesartan (150 mg/d; n = 211) or HCTZ (12.5 mg/d; n = 215), titrated to 300 mg/day and 25 mg/day respectively. In a second part of the study (weeks 16-28), patients initially randomised to irbesartan received additional HCTZ and vice versa. At week 16 both irbesartan and HCTZ had no effect on insulin resistance measured by the Matzuda index and beta-cell function. Similarly, in the second part of the study (week 16-28) no differences between irbesartan and HCTZ with respect to glucose metabolism were observed. However, irbesartan induced beneficial changes in high-sensitivity-C-reactive protein (hs-CRP) (irbesartan: -5.5 +/- 5.2%; HCTZ + 19.9 +/- 6.5%, p = 0.0024) and in urinary albumin/creatinine ratio (ACR) (irbesartan: -13%; HCTZ ...Continue Reading

References

Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Mar 30, 2002·The Journal of International Medical Research·C TopM Danaci
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Nov 15, 2003·Lancet·Fiona Turnbull, UNKNOWN Blood Pressure Lowering Treatment Trialists' Collaboration
Jun 8, 2004·The Journal of Clinical Endocrinology and Metabolism·G H GoossensM A van Baak
May 17, 2005·Cardiovascular Diabetology·Cristiana VitaleGiuseppe M C Rosano
Jun 9, 2005·Hypertension·Ronald ClasenUlrich Kintscher
Sep 27, 2005·Lancet·K George M M AlbertiUNKNOWN IDF Epidemiology Task Force Consensus Group
Aug 22, 2006·Metabolism: Clinical and Experimental·Jutta M NagelKlaus G Parhofer
Jun 8, 2007·The New England Journal of Medicine·Earl S FordSimon Capewell
Jun 20, 2008·Diabetes, Obesity & Metabolism·George BakrisUNKNOWN STAR Investigators
Sep 11, 2008·Expert Opinion on Therapeutic Targets·Ulrich KintscherThomas Unger
Nov 5, 2008·Hypertension·Suma Dronavalli, George L Bakris
Feb 28, 2009·World Journal of Gastroenterology : WJG·Eugen Florin GeorgescuLiliana Vancica
Apr 29, 2009·Transplant Immunology·T K HendrikxC C Baan

❮ Previous
Next ❯

Citations

Jan 19, 2013·Therapeutic Advances in Cardiovascular Disease·Elaina L MarinikKevin P Davy
Jun 8, 2012·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Claudio Borghi, Arrigo F G Cicero
Feb 24, 2015·Expert Review of Pharmacoeconomics & Outcomes Research·Claudio BorghiArrigo F G Cicero

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.